Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,707 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infusion Clear all
Completed Phase 3 Interventional

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

NCT00003440
View directory record Official record
Conditions
HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
paclitaxel, trastuzumab, quality-of-life assessment, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480
View directory record Official record
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Not listed Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

NCT04688853
View directory record Official record
Conditions
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
TEG002
Biological
Lead sponsor
Gadeta B.V.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional

Efficacy Study of Continuous Intraarticular Infusion in Patients Undergoing Arthroscopic Knee and Shoulder Operations

NCT00314457
View directory record Official record
Conditions
ACL Repair, Meniscectomy, Bankart Repair
Interventions
Bupivacaine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
11 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2009 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions

NCT01211366
View directory record Official record
Conditions
Transfusion
Interventions
Cell Saver RBCs, Conventional volume infusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

NCT00891137
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
human myeloid progenitor cells
Biological
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Orange, California • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

NCT00046072
View directory record Official record
Conditions
Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions
E5564
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
17
States / cities
Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

NCT04599075
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy, High Risk
Interventions
Insulin
Drug
Lead sponsor
Gianna Wilkie
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00066794
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
97
States / cities
Mobile, Alabama • Tucson, Arizona • Orange, California + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Intermittent Bolus vs Continuous Infusion Via ESP Catheters RCT

NCT05642416
View directory record Official record
Conditions
Post Operative Pain
Interventions
Continuous Infusion of ropivacaine, Intermittent bolus of ropivacaine
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

NCT00303667
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 19, 2026, 5:23 AM EDT
Completed No phase listed Observational

Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

NCT06096064
View directory record Official record
Conditions
Unfractionated Heparin
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed No phase listed Observational

Monitoring the Peripheral Intravenous Infusion Site for Infiltration and Extravasation

NCT01476293
View directory record Official record
Conditions
Infiltration, Extravasation, IV Infiltration, IV Extravasation, Extravasation of Diagnostic and Therapeutic Materials
Interventions
Not listed
Lead sponsor
ivWatch, LLC
Industry
Eligibility
Up to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

NCT04055844
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

NCT06730828
View directory record Official record
Conditions
Atrial Fibrillation, Postoperative
Interventions
The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Combination Product
Lead sponsor
Helios Cardio Inc.
Industry
Eligibility
20 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

NCT02630901
View directory record Official record
Conditions
Psoriasis
Interventions
PRX003, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT05863195
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
Biological · Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRX002 in Healthy Subjects

NCT02095171
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PRX002, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

NCT03274453
View directory record Official record
Conditions
Spinal Fusion
Interventions
Ketamine, Saline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 19, 2026, 5:23 AM EDT
Withdrawn Phase 1 Interventional

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

NCT00661336
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
buthionine sulfoximine, melphalan, microarray analysis, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
49
States / cities
Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Results available

Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair

NCT02075411
View directory record Official record
Conditions
Injury of Anterior Cruciate Ligament
Interventions
bupivacaine, continuous perineural infusion catheter
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

NCT01116102
View directory record Official record
Conditions
Dehydration
Interventions
Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain

NCT00899600
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Ketamine, Normal saline
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 19, 2026, 5:23 AM EDT